Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous or Homozygous Familial Hypercholesterolemia

Interventions

DRUG: Inclisiran

Sponsor

Novartis Pharmaceuticals